{"id":389,"date":"2020-02-16T11:13:22","date_gmt":"2020-02-16T05:43:22","guid":{"rendered":"https:\/\/medicineplexus.com\/?p=389"},"modified":"2020-02-16T11:13:22","modified_gmt":"2020-02-16T05:43:22","slug":"evaluation-of-drugs-in-the-management-of-bronchial-asthma","status":"publish","type":"post","link":"https:\/\/medicineplexus.com\/evaluation-of-drugs-in-the-management-of-bronchial-asthma\/","title":{"rendered":"Evaluation of drugs in the management of bronchial asthma"},"content":{"rendered":"\n
Evaluation of drugs in the management of bronchial asthma<\/strong><\/p>\n\n\n\n Problem statement<\/strong><\/p>\n\n\n\n Adverse effects \u2013<\/p>\n\n\n\n LABAs \u2013 increased mortality in salmeterol groups compared to placebo, with more in African Americans. Increased the risk of severe exacerbations driven by the number of asthma related hospitalizations, especially in children aged 4 to 11 years.<\/p>\n\n\n\n Budesonide\/formoterol combination – SMART trials included respiratory tract infection, pharyngitis, rhinitis, bronchitis, sinusitis, headache, and aggravated asthma. (Sequential, multiple assignment, randomized trial (SMART) designs)<\/p>\n\n\n\n Omalizumab \u2013 Anaphylaxis, atherothrombotic events.<\/p>\n\n\n\n 2009, the package inserts for montelukast, zafirlukast, and zileuton<\/strong> were updated to include neuropsychiatric events \u2013 association with suicide and suicidal events.(0.01%)<\/p>\n\n\n\n